Pharmaceuticals
Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $2 Mn in 2022 and is predicted to grow at a CAGR of 6.3% from 2023 to 2030, to US $4 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, increased awareness, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others
Buy Now
Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $2 Mn in 2022 and is projected to reach US $4 Mn in 2030, exhibiting a CAGR of 6.3% during the forecast period.
ADPKD, a hereditary disorder characterized by gene mutations (PKD1 and PKD2), leads to the development of fluid-filled cysts in multiple organs, predominantly in the kidneys, resulting in their enlargement (renomegaly). This progression often culminates in kidney failure (ESKD). Symptoms commonly include pain, recurrent infections, and fatigue. Although incurable, the management of ADPKD primarily focuses on preventing complications and managing symptoms. Tolvaptan (Jinarc) manufactured by Otsuka Pharmaceuticals, an approved treatment for ADPKD, acts as a vasopressin blocker, reducing cyst formation in specific patients. Pain management, lifestyle adaptations, and various medications targeting related issues like hypertension offer additional treatment avenues.
There is evidence that the prevalence of ADPKD is on the rise in the Philippines due to the statistically increasing geriatric population having considerable genetic predispositions and aging-related health concerns. The market is therefore driven by major factors like the rising prevalence of cases, government initiatives and public health programs, and increased awareness in the population. However, conditions such as high costs of advanced treatment, dependence on imported medicine, and others hinder the growth and potential of the market.
Market Dynamics
Market Growth Drivers
Surge in the prevalence of ADPKD: According to evidence, the anticipated growth in the Philippines' population, especially the aging demographic, is expected to result in a higher number of individuals prone to ADPKD. This could be attributed to genetic predisposition or health factors concerned with aging. The changes in modifiable risk factors such as diet and lack of physical inactivity contribute to increased prevalence. These factors result in patients requiring advanced treatments, resulting in the growth of the market.
Government initiatives: Government initiatives aimed at addressing rare diseases and chronic conditions, involving funding allocations for research and development by the Philippines Society for Orphan Diseases, pave the way for future progress in ADPKD treatment. This could potentially enhance medication accessibility through the expansion of healthcare programs, allowing market expansion.
Increased awareness: Increasing public awareness and educational campaigns promote early diagnosis, enabling timely interventions and potentially widening the market for treatments focused on slowing the advancement of the disease. Groups such as the Philippine Society of Nephrology work towards improving patient access and care, influencing evidence-based policy decisions by gathering data that propels the therapeutics market.
Market Restraints
High costs of treatment: Tolvaptan, the existing primary medication for ADPKD, alongside potential upcoming therapies, still pose considerable financial challenges for patients despite PhilHealth coverage. This could burden patients financially, potentially limiting treatment accessibility and leading to non-adherence or delays, affecting the market's outreach.
Dependence on Imported Medicines: The Philippines heavily depends on imported medications for ADPKD, leaving the market vulnerable to currency fluctuations and potential disruptions in the supply chain. This situation can affect patient access and treatment consistency, introducing instability that could hinder market growth
Limited research and development: In contrast to other significant markets, the Philippines' involvement in ADPKD research might be relatively limited, which could slow down the development and accessibility of new treatment options for patients. This situation restricts market diversity and the potential for innovation.
Healthcare Policies and Regulatory Landscape
In the Philippines, healthcare regulations and licensing are overseen by the Department of Health (DOH) and the Philippine Health Insurance Corporation (PhilHealth). Acquiring a license for healthcare products in the Philippines requires adherence to the regulations established by the DOH and PhilHealth.
Acquiring a license for healthcare products in Philippines necessitates adherence to regulations established by the DOH and PhilHealth. These entities oversee and supervise healthcare services, including the approval and monitoring of medical and healthcare products. To gain registration and marketing authorization for pharmaceuticals and medical devices, companies must obtain approval from the DOH. This process involves submitting technical and scientific data to validate the product's safety, quality, and effectiveness.
Philippine healthcare policy and regulatory framework involve numerous authorities and agencies, with the DOH holding a pivotal role in healthcare product regulation. Both the public and private healthcare sectors in the country offer diverse opportunities for companies operating within the healthcare industry
Competitive Landscape
Key Players
- Otsuka Pharmaceutical Co., Ltd
- Regulus Therapeutics
- Palladio Biosciences
- Reata Pharmaceuticals
- Galapagos NV
- Exelixis Inc
- AceLink Therapeutics, Inc
- Sanofi
- Xortx Therapeutics
- Pano Therapeutics
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Philippines Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Segmentation
By Treatment
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By Route of Administration
- Oral
- Parenteral
- Others
By End User
- Hospitals
- Speciality Clinics
- Surgical Centres
- Others
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Pharmaceuticals
Philippines Rotavirus Vaccine Market Analysis
Pharmaceuticals
Austria Radiotherapy Market Analysis
Pharmaceuticals
Global Lung Cancer Drugs Market Analysis
Related reports (by geography)
Medical Devices
